Amgen sees highest patent filings and grants during July in Q3 2023
Amgen saw the highest growth of 98% in patent filings in August and 130% in grants in September in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 86% and grants by 99%. GlobalData's DataBook provides a comprehensive analysis of Amgen's patent filings and grants. Buy the databook here. Amgen has been focused on protecting inventions in European Patent Office (E/P) with 91 publications in Q3 2023The European Patent Office (E/P) Patent Office dominates the patent filings and grants with nearly 16% filings and 17% grants. The European Patent Office (E/P), United States(US), Australia(AU), and Japan(JP) patent Office are among the top ten patent offices where Amgen is filings its patents. Among the top granted patent authorities, Amgen has 19% of its grants in United States(US), 17% in European Patent Office (E/P), and 13% in Canada(CA). Johnson & Johnson could be the strongest competitor for AmgenIn terms of grant share, Amgen stands in five position among its competitors. Johnson & Johnson and Pfizer secured the top positions according to recent patent publication data. Patents related to rare diseases and data science lead Amgen's portfolioAmgen has the highest number of patents in rare diseases followed by, data science and artificial intelligence. For rare diseases, nearly 29% of patents were filed and 39% of patents were granted in Q3 2023. Drug delivery devices related patents lead Amgen portfolio followed by pancreatic cancer, and lung cancerAmgen has highest number of patents in drug delivery devices followed by pancreatic cancer, lung cancer, colorectal tumor and rheumatoid arthritis. For drug delivery devices, nearly 4% of patents were filed and 4% of patents were granted in Q3 2023. For comprehensive analysis of Amgen's filings and grants, buy the databook here.
Access and buy GlobalData’s databook on the latest filings and grants activity for Amgen here.
What's Your Reaction?
